Reference : Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy De...
Scientific journals : Article
Life sciences : Multidisciplinary, general & others
http://hdl.handle.net/10993/50439
Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism.
English
Albrecht, Marco [> >]
Kogan, Yuri [> >]
Kulms, Dagmar [> >]
Sauter, Thomas mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)]
2022
Pharmaceutics
14
2
Yes (verified by ORBilu)
International
1999-4923
1999-4923
[en] CYP3A4 ; DDI ; MCPK ; PK ; dabrafenib ; enzyme induction ; enzyme kinetics ; metabolism
[en] Dabrafenib inhibits the cell proliferation of metastatic melanoma with the oncogenic BRAF(V600)-mutation. However, dabrafenib monotherapy is associated with pERK reactivation, drug resistance, and consequential relapse. A clinical drug-dose determination study shows increased pERK levels upon daily administration of more than 300 mg dabrafenib. To clarify whether such elevated drug concentrations could be reached by long-term drug accumulation, we mechanistically coupled the pharmacokinetics (MCPK) of dabrafenib and its metabolites. The MCPK model is qualitatively based on in vitro and quantitatively on clinical data to describe occupancy-dependent CYP3A4 enzyme induction, accumulation, and drug-drug interaction mechanisms. The prediction suggests an eight-fold increase in the steady-state concentration of potent desmethyl-dabrafenib and its inactive precursor carboxy-dabrafenib within four weeks upon 150 mg b.d. dabrafenib. While it is generally assumed that a higher dose is not critical, we found experimentally that a high physiological dabrafenib concentration fails to induce cell death in embedded 451LU melanoma spheroids.
Researchers ; Professionals
http://hdl.handle.net/10993/50439
H2020 ; 642295 - MEL-PLEX - Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
pharmaceutics-14-00310.pdfPublisher postprint3.14 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.